Accessibility Menu
Cronos Group logo

Cronos Group(NASDAQ) CRON

Current Price$2.79
Market Cap$1.04BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)+1,585%
5 Year-61%
1 Year+30%
1 Month+5%
Cronos Group last closing stock price
MetricPriceDate
Last closeUSD 2.782026-07-22
Cronos Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.46%USD 2.742026-07-15
1 month+4.91%USD 2.652026-06-22
3 month+6.92%USD 2.602026-04-23
Year to date+5.7%USD 2.632025-12-31
1 year+29.91%USD 2.142025-07-22
3 year+50.27%USD 1.852023-07-21
5 year-61.12%USD 7.152021-07-23
Since inception+1,584.85%USD 0.172016-07-12

Cronos Group Financials at a Glance

Market Cap

$1.04BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$205.68M

Net Income (TTM)

-$2.01M

EPS (TTM)

-$0.00

P/E Ratio

-631.82

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Price

$2.79

Volume

151

Open

$2.80

Previous Close

$2.78

Daily Range

$2.77 - $2.85

52-Week Range

$1.93 - $3.43

Estimated Earnings Date

Aug 6, 2026

CRON News

GettyImages-cigarettes and coins lying on a table

What Does Altria Own?

Matt DiLalloJun 1, 2026
Field of green tobacco leaves.jpg

Best Tobacco Stocks for 2026 and How to Invest

Jeremy BowmanMay 13, 2026
A cannabis leaf on top of a $100 bill.

Best Cannabis ETFs to Buy in 2026 and How to Invest

Keith SpeightsMay 8, 2026
Chalboard drawings of a marijuana leaf with accompanying stock, bar and pie charts.

Why Cronos Group Stock Popped 9% Today

Rich SmithNov 12, 2024
Cannabis leaf in front of person's face

Why Cronos Group Stock Is Sinking Today

Keith SpeightsAug 27, 2024
Person in a field smoking a marijuana cigarette

Why Investors Were High on Cronos Group Today

Eric VolkmanAug 8, 2024
Marijuana flower on fire

Why Investors Were so High on Cronos Stock This Week

Eric VolkmanSep 1, 2023
Person working with marijuana plant

Why Cronos Group Stock Tanked Today

Eric VolkmanJul 6, 2023
Page 1

CRON: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cronos Group

Cronos Group makes cannabis products for medical and recreational users. It helps people manage health needs and provides options for relaxation. The company sells its brands through pharmacies and retail stores worldwide.

What Cronos Sells

  • Spinach: Adult-use brand offering dried flower, pre-rolls, and edibles for recreational consumers.
  • PEACE NATURALS: Global medical brand providing flower and tinctures, which are liquid extracts taken by mouth.
  • Lord Jones: Premium line selling concentrates and vaporizers, which turn cannabis oil into inhalable mist.
  • LIT: Value-focused medical brand designed to provide affordable cannabis flower in Europe and Israel.

Strategic Moves Across Borders

  • Obtained majority control of Cronos GrowCo in July 2024 to secure a steady supply of raw materials.
  • Expanded medical cannabis distribution into the United Kingdom in February 2024 through a third-party partnership.
  • Signed an agreement to acquire CanAdelaar to enter the controlled cannabis supply experiment in the Netherlands.
  • Launched the Lord Jones brand in the Israeli medical market in February 2026 with flower products.
  • Formed a strategic partnership with Cansativa in September 2023 to distribute medical products in Germany.

What Sets the Company Apart

Cronos manages an international distribution network that connects Canadian production with patients in Israel, Germany, and Australia. It also benefits from a strategic partnership with Altria for research, regulatory support, and brand management.

A Look at the Numbers

  • Net revenues reached $91.3 million in Q4 2025, up 201.3% from $30.3 million in Q4 2024.
  • Operating income improved to $7 million in Q4 2025, up from an $11.4 million loss in Q4 2024.
  • Free cash flow grew to $9.9 million in Q4 2025, up 146.1% from the previous year.
  • Net income worsened to -$1.8 million in Q4 2025, down from $43.7 million in Q4 2024.
  • Two major Canadian retail distributors accounted for 43% of total net revenues for the 2025 fiscal year.

Bottom Line

Cronos Group has evolved from a startup into a global producer of cannabinoids, which are natural chemical compounds in cannabis. Its focus on brand building and international partnerships helps it navigate different legal markets worldwide.

AI Generated • May 2, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

610

CEO

Michael Ryan Gorenstein

Website

www.thecronosgroup.com

Headquarters

Stayner, ON M5V 2H1, CA

CRON Financials

Key Financial Metrics (TTM)

Gross Margin

42.19%

Operating Margin

-7.77%

Net Income Margin

-1.29%

Return on Equity

-0.19%

Return on Capital

-1.63%

Return on Assets

-0.18%

Earnings Yield

-0.16%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.04BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

373.66M

Volume

151

Avg. Volume

1.24M

Financials (TTM)

Gross Profit

$67.49M

Operating Income

-$291.85K

EBITDA

-$12.08M

Operating Cash Flow

$38.91M

Capital Expenditure

-$12.43M

Free Cash Flow

$26.47M

Cash & ST Invst.

$824.56M

Total Debt

$1.32M

Cronos Group Performance Analysis

Cronos Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 86,749,00016.5%
20232023-12-31USD 87,241,0000.6%
20242024-12-31USD 117,615,00034.8%
20252025-12-31USD 146,587,00024.6%
Cronos Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-303.7%
Q32025-09-308.6%
Q42025-12-31151.3%
Q12026-03-31-51.2%
Cronos Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.45-58.2%
20232023-12-31USD -0.19-56.7%
20242024-12-31USD 0.11N/A
20252025-12-31USD -0.02N/A
Cronos Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-732.9%
Q32025-09-30167.0%
Q42025-12-31-107.0%
Q12026-03-31855.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$44.58M

+38.2%

Gross Profit

$18.47M

+34.5%

Gross Margin

41.42%

N/A

Market Cap

$1.04BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.70M

N/A

Employees

610

N/A

Net Income

$13.56M

+121.5%

EBITDA

$2.24M

+430.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$824.56M

-1.6%

Total Debt

$1.32M

-27.6%

Accounts Receivable

$52.54M

+65.5%

Inventory

$48.84M

+41.1%

Long Term Debt

$1.15M

+36.4%

Short Term Debt

$169.56K

-82.6%

Return on Assets

-0.18%

N/A

Return on Invested Capital

-1.10%

N/A

Free Cash Flow

$8.90M

+151.0%

Operating Cash Flow

$10.75M

+612.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PCRXPacira BioSciences, Inc.
$25.59-0.74%
COLLCollegium Pharmaceutical, Inc.
$34.72-3.15%
PHATPhathom Pharmaceuticals, Inc.
$11.70+4.00%
IRMDIRadimed Corporation
$94.08-0.94%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About CRON

What is the current price of Cronos Group?

Cronos Group is trading at $2.78 per share.

What is the 52-week range for Cronos Group?

Over the past 52 weeks, Cronos Group has traded between $1.93 and $3.43.

How much debt does Cronos Group have?

As of the most recent reporting period, Cronos Group reported total debt of $1.31M.

How much cash does Cronos Group have on hand?

Cronos Group reported $821.86M in cash and cash equivalents in its most recent financial results.

What is Cronos Group’s dividend yield?

Cronos Group does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services